Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma

British Journal of Cancer

Volumn 73, Issue 9, 1996, Pages 1074-1079

  Blomqvist, C ^a   Risteli, L ^b   Risteli, J ^b   Virkkunen, P ^a   Sarna, S ^a   Elomaa, I ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

Bone metastases; Breast neoplasm; Collagen; ICTP; Metabolism; PICP

Indexed keywords

ALKALINE PHOSPHATASE; CALCITONIN; CALCIUM ION; COLLAGEN TYPE 1; OSTEOCALCIN;

AMINO TERMINAL SEQUENCE; ARTICLE; BONE METABOLISM; BONE METASTASIS; BONE SCINTISCANNING; BREAST CARCINOMA; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; FEMALE; HUMAN; PRIORITY JOURNAL; RADIOGRAPHY;

EID: 0029996436     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.207     Document Type: Article

References (36)

1. ABILDGAARD N, NIELSEN JL AND HEICKENDORFF L. (1994). Connective tissue components in serum in multiple myeloma: analyses of propeptides of type I and type III procollagens, type I collagen telopeptide, and hyaluronan. Am. J. Hematol., 46, 173-178.
2. BITRAN JD, BEKDERMAN C AND DESSER RK. (1980). The predictive value of serial bone scans in assessing response to chemotherapy in advanced breast cancer. Cancer, 45, 1562-1568.
3. BLOMQVIST C, ELOMAA I, VIRKKUNEN P, PORKKA L, KARONEN S-L, RISTELl L AND RISTELI J. (1987). The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy and biochemical markers of bone metabolism. Cancer, 60, 2907-2912.
4. BLOMQVIST C, ELOMAA I, PORKKA L, KARONEN S-L AND LAMBERG-ALLARDT C. (1988). Evaluation of salmon calcitonin treatment in bone metastases from breast cancer. A controlled trial. Bone, 9, 45-51.
5. BONJOUR JP, PHILIPPE J AND GUELPA G. (1988). Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone, 9, 123-130.
6. CHARLES P, MOSEKILDE L, RISTELI L, RISTELI J AND ERIKSEN EF. (1994). Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner., 24, 81-94.
7. COOMBES RC, DADY P, PARSONS C, MCCREADY VR, FORD HT, GAZET J-C AND POWLES TJ. (1983). Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer, 52, 610-614.
8. De la PIEDRA C, DIAZ MM, DIAZ DE, LOPEZ GE, GONZALEZ PE, CARAMELO C AND RAPADO A. (1994). Serum concentrations of carboxyterminal cross-linked telopeptide of type I collagen (ICTP), serum tartrate resistant acid phosphatase, and serum levels of intact parathyroid hormone in parathyroid hyperfunction. Scand. J. Clin. Lab. Invest., 54, 11-15.
9. EBERHARDT K, THORBJORN JL, HORSLEV PK, PETTERSSON H, LORENZEN I AND WOLLHEIM F. (1990). Serum aminoterminal type III procollagen peptide in early rheumatoid arthritis: relation to disease activity and progression of joint damage. Clin. Exp. Rheumatol., 8, 335-340.
10. ELOMAA I, VIRKKUNEN P, RISTELI L AND RISTELI J. (1992). Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br. J. Cancer, 66, 337-341.
11. ERIKSEN EF, CHARLES P, MELSEN F, MOSEKILDE L, RISTELI L AND RISTELI J. (1993). Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J. Bone Miner. Res., 8, 127-132.
12. FILIPPONI P, PEDETTI M, BEGHE F, GIOVAGNINI B, MIAM M AND CRISTALLINI S. (1994). Effects of two different bisphosphonates on Paget's disease of bone: ICTP assessed. Bone, 15, 261-267.
13. FREVERT EU, BIESTER A, MULLER MJ, SCHMIDT GH, VON ZUR MUHLEN A AND BRABANT G. (1994). Markers of bone metabolism during short-term administration of thyroxine in healthy volunteers. Eur. J. Endocrinol., 131, 145-149.
14. GARDNER MJ AND ALTMAN DG. (1989). Statistics with Confidence. British Medical Journal: London.
15. GARDNER SB, WINTER PD AND GARDNER MJ. (1989). CIA version 1.0. MJ Gardner and British Medical Journal: London.
16. HAKALA M, RISTELI L, MANELIUS J, NIEMINEN P AND RISTELI J. (1993). Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis. Ann. Rheum. Dis., 52, 866-869.
17. HASSELBALCH H, JUNKER P, HORSLEV PK, LISSE I AND BENTSEN KD. (1990). Procollagen type III aminoterminal peptide in serum in idiopathic myelofibrosis and allied conditions: relation to disease activity and effect of chemotherapy. Am. J. Hematol., 33, 18-26.
18. HAYWARD JL, RUBENS R, CARBONE PP, HEUSON J-C, KUMAOKA S AND SEGALOF FA. (1977). Assessment of response to therapy in advanced breast cancer. Br. J. Cancer, 35, 292-298.
19. KAUPPILA A, PUISTOLA U, RISTELI J AND RISTELI L. (1989). Amino-terminal propeptide of type III procollagen: a new prognosis indicator in human ovarian cancer. Cancer Res., 49, 1885-1889.
20. KERSTJENS HA, POSTMA DS, VAN DOORMAAL JJ, VAN ZANTEN AK, BRAND PL, DEKHUIJZEN PN AND KOETER GH. (1994). Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group. Thorax, 49, 652-656.
21. KYLMÄLÄ T, TAMMELA T, RISTELI L, RISTELI J, TAUBE T AND ELOMAA I. (1993). Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur. J. Cancer, 29A, 821-825.
22. MELKKO J, NIEMI S, RISTELI L AND RISTELI J. (1990). Radio-immunoassay of the carboxyterminal propeptide of human type I procollagen. Clin. Chem., 36, 1328-1332.
23. NIEMELA O, RISTELI J, BLAKE JE, RISTELI L, COMPTON KV AND ORREGO H. (1990). Markers of fibrogenesis and basement membrane formation in alcoholic liver disease: relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology, 98, 1612-1619.
24. PRICE PA AND NISHIMOTO SK. (1980). Radioimmunoassay for the vitamin-K dependent protein of bone and its discovery in plasma. Proc. Natl Acad. Sci. USA, 77, 2234-2238.
25. RISTELI J, ELOMAA I, NIEMI S, NOVAMO A AND RISTELI L. (1993). Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin. Chem., 39, 635-640.
26. ROBERTSON JF, PEARSON D, PRICE MR, SELBY C, BLAMEY RW AND HOWELL A. (1991). Objective measurement of therapeutic response in breast cancer using tumour markers. Br. J. Cancer, 64, 757-763.
27. SARTORIO A, CONTI A AND MONZANI M. (1993a). New markers of bone and collagen turnover in children and adults with growth hormone deficiency. Postgrad. Med. J., 69, 846-850.
28. SARTORIO A, CONTI A, MONZANI M, MORABITO F AND FAGLIA G. (1993b). Growth hormone treatment in adults with GH deficiency: effects on new biochemical markers of bone and collagen turnover. J. Endocrinol. Invest., 16, 893-898.
29. STATXACT. (1992). Version 2.11. Cytel Software Corporation: Cambridge, MA.
30. TAUBE T, FRANSSILA K, RISTELI L, RISTELI J AND ELOMAA I. (1992). Monitoring of multiple myeloma and bone marrow fibrosis with aminoterminal propeptide of type III collagen (PIIINP). Br. J. Haematol., 82, 32-37.
31. TAUBE T, KYLMÄLÄ TC, LAMBERQ-ALLARDT C, TAMMELA TLJ AND ELOMAA I. (1994). The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double blind randomised placebo controlled study. Eur. J. Cancer, 30, 751-758.
32. TOMAS C, PENTTINEN J, RISTELI J, RISTELI E, VUORI J AND KAUPPILA A. (1990). Serum concentrations of CA 125 and aminoterminal propeptide of type III procollagen (PIIINP) in patients with endometrial carcinoma. Cancer, 66, 2399-2406.
33. TOMAS C, RISTELI J, RISTELI E, VUORI J AND KAUPPILA A. (1991). Use of various epithelial tumor markers and a stromal marker in the assessment of cervical carcinoma. Obstet. Gynecol., 77, 566-572.
34. VALIMAKI MJ, TAHTELA R, JONES JD, PETERSON JM AND RIGGS BE. (1994). Bone resorption in healthy and osteoporotic postmenopausal women: comparison markers for serum carboxy-terminal telopeptide of type I collagen and urinary pyridinium cross-links. Eur. J. Endocrinol., 131, 258-262.
35. WIKLUND TA, ELOMAA I, BLOMQVIST CP, RISTELI L AND RISTELI J. (1992). Type III collagen metabolism in soft tissue sarcomas. Br. J. Cancer, 65, 193-196.
36. WIKLUND TA, BLOMQVIST CP, RISTELI E, RISTELI J AND ELOMAA I. (1993). Impact of chemotherapy on collagen metabolism: a study of serum PIIINP (aminoterminal propeptide of type III procollagen) in advanced sarcomas. J. Cancer Res. Clin. Oncol., 119, 160-164.